Educational guide
Peptides as multifunctional players in cancer therapy
Ladner, R. C., Sato, A. K., Gorzelany, J. & de Souza, M. Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Disco. 9 , 525–529 (2004). CAS Google Scholar Fosgerau, K. & Hoffmann, T. Peptide therapeutics: current status and future di
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Ladner, R. C., Sato, A. K., Gorzelany, J. & de Souza, M. Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Disco. 9, 525–529 (2004).
Fosgerau, K. & Hoffmann, T. Peptide therapeutics: current status and future directions. Drug Disco. 20, 122–128 (2015).
Blanco‐Míguez, A. et al. From amino acid sequence to bioactivity: the biomedical potential of antitumor peptides. Protein Sci. 25, 1084–1095 (2016).
Wang, L. et al. Therapeutic peptides: current applications and future directions. Signal Transduct. Target Ther. 7, 48 (2022).
Kessel, C. et al. Multimerization of peptide mimotopes for blocking of factor VIII neutralizing antibodies. Chem. Med. Chem. 4, 1364–1370 (2009).
Knittelfelder, R., Riemer, A. B. & Jensen-Jarolim, E. Mimotope vaccination–from allergy to cancer. Expert Opin. Biol. Ther. 9, 493–506 (2009).
Tong, A. H. Y. et al. A combined experimental and computational strategy to define protein interaction networks for peptide recognition modules. Science 295, 321–324 (2002).
Liu, M., Fang, X., Yang, Y. & Wang, C. Peptide-enabled targeted delivery systems for therapeutic applications. Front Bioeng. Biotechnol. 9, 701504 (2021).
Chen, Y. et al. Sortase A-mediated cyclization of novel polycyclic RGD peptides for ανβ3 integrin targeting. Bioorg. Med Chem. Lett. 73, 128888 (2022).
Echigo, H. et al. Development and evaluation of a theranostic probe with RGD peptide introduced platinum complex to enable tumor-specific accumulation. Bioorg. Med. Chem. 70, 116919 (2022).
Kato, N. et al. Synthesis and evaluation of a novel adapter lipid derivative for preparation of cyclic peptide-modified PEGylated liposomes: Application of cyclic RGD peptide. Eur. J. Pharm. Sci. 176, 106239 (2022).
Chen, K. & Chen, X. Integrin targeted delivery of chemotherapeutics. Theranostics 1, 189 (2011).
Sugahara, K. N. et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer cell 16, 510–520 (2009).
Ruoslahti, E. Tumor penetrating peptides for improved drug delivery. Adv. Drug Deliv. Rev. 110, 3–12 (2017).
Teesalu, T., Sugahara, K. N., Kotamraju, V. R. & Ruoslahti, E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc. Natl Acad. Sci. USA 106, 16157–16162 (2009).
Chen, T. et al. nRGD modified lycobetaine and octreotide combination delivery system to overcome multiple barriers and enhance anti-glioma efficacy. Colloids Surf. B 156, 330–339 (2017).
Su, S., Wang, H., Liu, X., Wu, Y. & Nie, G. iRGD-coupled responsive fluorescent nanogel for targeted drug delivery. Biomaterials 34, 3523–3533 (2013).
Yu, K.-F. et al. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation. Int J. Nanomed. 8, 2473 (2013).
Fogal, V., Zhang, L., Krajewski, S. & Ruoslahti, E. Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res. 68, 7210–7218 (2008).
Karmali, P. P. et al. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine 5, 73–82 (2009).
Hardwick, J. S. et al. Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling. Mol. Cancer Ther. 4, 413–425 (2005).
Yu, D.-H., Lu, Q., Xie, J., Fang, C. & Chen, H.-Z. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials 31, 2278–2292 (2010).
Obiri, N., Siegel, J., Varricchio, F. & Puri, R. Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin. Exp. Immunol. 95, 148–155 (1994).
Kawakami, K., Leland, P. & Puri, R. K. Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells. Cancer Res. 60, 2981–2987 (2000).
Kawakami, M. et al. Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy. Clin. Cancer Res. 8, 3503–3511 (2002).
Kim, J.-H. et al. Facilitated intracellular delivery of peptide-guided nanoparticles in tumor tissues. J. Control Release 157, 493–499 (2012).
Chi, L. et al. Enhanced delivery of liposomes to lung tumor through targeting interleukin-4 receptor on both tumor cells and tumor endothelial cells. J. Control Release 209, 327–336 (2015).
Jeon, J. O. et al. Designed nanocage displaying ligand-specific peptide bunches for high affinity and biological activity. ACS Nano 7, 7462–7471 (2013).
Guruprasath, P. et al. Interleukin-4 receptor-targeted delivery of Bcl-xL siRNA sensitizes tumors to chemotherapy and inhibits tumor growth. Biomaterials 142, 101–111 (2017).
Namgung, R. et al. Poly-cyclodextrin and poly-paclitaxel nano-assembly for anticancer therapy. Nat. Commun. 5, 1–12 (2014).
de Groot, A. E. et al. Targeting interleukin 4 receptor alpha on tumor-associated macrophages reduces the pro-tumor macrophage phenotype. Neoplasia 32, 100830 (2022).
Bankaitis, K. V. & Fingleton, B. Targeting IL4/IL4R for the treatment of epithelial cancer metastasis. Clin. Exp. Metastasis 32, 847–856 (2015).
Figueiredo, P. et al. Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy. Acta Biomater. 133, 231–243 (2021).
Johnsen, K. B. et al. A comprehensive overview of exosomes as drug delivery vehicles—endogenous nanocarriers for targeted cancer therapy. Biochim Biophys. Acta Rev. Cancer 1846, 75–87 (2014).
Alvarez-Erviti, L. et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29, 341–345 (2011).
Tian, Y. et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 35, 2383–2390 (2014).
Ohno, S.-i et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 21, 185–191 (2013).
Morishita, M., Takahashi, Y., Nishikawa, M., Ariizumi, R. & Takakura, Y. Enhanced class I tumor antigen presentation via cytosolic delivery of exosomal cargos by tumor-cell-derived exosomes displaying a pH-sensitive fusogenic peptide. Mol. Pharm. 14, 4079–4086 (2017).
Gunassekaran, G. R., Vadevoo, S. M. P., Baek, M.-C. & Lee, B. M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials 278, 121137 (2021).
Zhan, Q. et al. Engineering blood exosomes for tumor-targeting efficient gene/chemo combination therapy. Theranostics 10, 7889 (2020).
Cheng, H. et al. Chimeric peptide engineered exosomes for dual-stage light guided plasma membrane and nucleus targeted photodynamic therapy. Biomaterials 211, 14–24 (2019).
Lim, W. A. & June, C. H. The principles of engineering immune cells to treat cancer. Cell 168, 724–740 (2017).
Maus, M. V. & June, C. H. Making better chimeric antigen receptors for adoptive T-cell therapy. Clin. Cancer Res. 22, 1875–1884 (2016).
Gunassekaran, G. R. et al. Non-genetic engineering of cytotoxic T cells to target IL-4 receptor enhances tumor homing and therapeutic efficacy against melanoma. Biomaterials 159, 161–173 (2018).
Cheng, H. et al. Stem cell membrane engineering for cell rolling using peptide conjugation and tuning of cell–selectin interaction kinetics. Biomaterials 33, 5004–5012 (2012).
Sarkar, D. et al. Engineered cell homing. Blood 118, e184–e191 (2011).
Johnstone, S. A., Gelmon, K., Mayer, L. D., Hancock, R. E. & Bally, M. B. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer Drug Des. 15, 151–160 (2000).
Luan, X. et al. Cytotoxic and antitumor peptides as novel chemotherapeutics. Nat. Prod. Rep. 38, 7–17 (2021).
Mai, J. C., Mi, Z., Kim, S.-H., Ng, B. & Robbins, P. D. A proapoptotic peptide for the treatment of solid tumors. Cancer Res. 61, 7709–7712 (2001).
Dufort, S. et al. Targeted delivery of a proapoptotic peptide to tumors in vivo. J. Drug Target 19, 582–588 (2011).
Jin, Y. et al. Nanosystem composed with MSNs, gadolinium, liposome and cytotoxic peptides for tumor theranostics. Colloids Surf. B 151, 240–248 (2017).
Ellerby, H. M. et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med 5, 1032–1038 (1999).
Permpoon, U. et al. Inhibition of tumor growth against chemoresistant cholangiocarcinoma by a proapoptotic peptide targeting interleukin-4 receptor. Mol. Pharm. 17, 4077–4088 (2020).
Vadevoo, S. M. P. et al. IL4 receptor–targeted proapoptotic peptide blocks tumor growth and metastasis by enhancing antitumor immunity anticancer activity of IL4R-targeted proapoptotic peptide. Mol. Cancer Ther. 16, 2803–2816 (2017).
Khan, F. et al. Identification of novel CD44v6-binding peptides that block CD44v6 and deliver a pro-apoptotic peptide to tumors to inhibit tumor growth and metastasis in mice. Theranostics 11, 1326 (2021).
Fantin, V. R. et al. A bifunctional targeted peptide that blocks HER-2 tyrosine kinase and disables mitochondrial function in HER-2-positive carcinoma cells. Cancer Res. 65, 6891–6900 (2005).
Arap, W. et al. Targeting the prostate for destruction through a vascular address. Proc. Natl Acad. Sci. USA 99, 1527–1531 (2002).
Jung, H.-K. et al. Bladder tumor-targeted delivery of pro-apoptotic peptide for cancer therapy. J. Control Release 235, 259–267 (2016).
Vadevoo, S. M. P. et al. Peptide-based targeted therapeutics and apoptosis imaging probes for cancer therapy. Arch. Pharm. Res. 42, 150–158 (2019).
Yamasaki, K. & Gallo, R. L. Antimicrobial peptides in human skin disease. Eur. J. Dermatol 18, 11–21 (2008).
Leuschner, C. & Hansel, W. Membrane disrupting lytic peptides for cancer treatments. Curr. Pharm. Des. 10, 2299–2310 (2004).
Yang, N., Lejon, T. & Rekdal, Ø. Antitumour activity and specificity as a function of substitutions in the lipophilic sector of helical lactoferrin‐derived peptide. J. Pept. Sci. 9, 300–311 (2003).
Han, J.-H. et al. Noxa mitochondrial targeting domain induces necrosis via VDAC2 and mitochondrial catastrophe. Cell Death Dis. 10, 1–13 (2019).
Warren, P. et al. In vitro targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two γ-linked glutamate residues at the COOH terminus. Cancer Res. 61, 6783–6787 (2001).
Ersahin, D., Doddamane, I. & Cheng, D. Targeted radionuclide therapy. Cancers 3, 3838–3855 (2011).
Costa, F. & Gumz, B. Octreotide–a review of its use in treating neuroendocrine tumours. Eur. Endocrinol. 10, 70 (2014).
Bodei, L., Pepe, G. & Paganelli, G. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Eur. Rev. Med Pharm. Sci. 14, 347–351 (2010).
Esser, J.-P. et al. Comparison of [177Lu-DOTA0, Tyr3] octreotate and [177Lu-DOTA0, Tyr3] octreotide: which peptide is preferable for PRRT? Eur. J. Nucl. Med. Mol. Imaging 33, 1346–1351 (2006).
Van de Wiele, C. et al. Biodistribution and dosimetry of 99mTc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J. Nucl. Med. 42, 1722–1727 (2001).
Laverman, P. et al. Targeting of a CCK2 receptor splice variant with 111In-labelled cholecystokinin-8 (CCK8) and 111In-labelled minigastrin. Eur. J. Nucl. Med. Mol. Imaging 35, 386–392 (2008).
La Manna, S., Di Natale, C., Florio, D. & Marasco, D. Peptides as therapeutic agents for inflammatory-related diseases. Int J. Mol. Sci. 19, 2714 (2018).
do Pazo, C., Nawaz, K. & Webster, R. M. The oncology market for antibody-drug conjugates. Nat. Rev. Drug Discov. 20, 583–584 (2021).
Hoppenz, P., Els-Heindl, S. & Beck-Sickinger, A. G. Peptide-drug conjugates and their targets in advanced cancer therapies. Front Chem. 8, 571 (2020).
Chavda, V. P., Solanki, H. K., Davidson, M., Apostolopoulos, V. & Bojarska, J. Peptide-drug conjugates: a new hope for cancer management. Molecules 27, 7232 (2022).
Raza Naqvi, S. A. et al. Insertion of a lysosomal enzyme cleavage site into the sequence of a radiolabeled neuropeptide influences cell trafficking in vitro and in vivo. Cancer Biother Radiopharm. 25, 89–95 (2010).
van Duijnhoven, S. M., Robillard, M. S., Nicolay, K. & Grüll, H. Tumor targeting of MMP-2/9 activatable cell-penetrating imaging probes is caused by tumor-independent activation. J. Nucl. Med. 52, 279–286 (2011).
Szabó, I. et al. Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug. Bioconjug Chem. 20, 656–665 (2009).
Lelle, M. et al. Octreotide-mediated tumor-targeted drug delivery via a cleavable doxorubicin–peptide conjugate. Mol. Pharm. 12, 4290–4300 (2015).
Hou, J. et al. RGD peptide conjugation results in enhanced antitumor activity of PD0325901 against glioblastoma by both tumor-targeting delivery and combination therapy. Int J. Pharm. 505, 329–340 (2016).
Gilad, Y. et al. Dual‐drug RGD conjugates provide enhanced cytotoxicity to melanoma and non‐small lung cancer cells. Pept. Sci. 106, 160–171 (2016).
Fan, M. et al. Design and biological activity of epidermal growth factor receptor-targeted peptide doxorubicin conjugate. Biomed. Pharmacother. 70, 268–273 (2015).
Regina, A. et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep‐2. Br. J. Pharm. 155, 185–197 (2008).
Topalian, S. L., Taube, J. M. & Pardoll, D. M. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science 367, eaax0182 (2020).
Valk, E., Rudd, C. E. & Schneider, H. CTLA-4 trafficking and surface expression. Trends Immunol. 29, 272–279 (2008).
Krummel, M. F. & Allison, J. P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459–465 (1995).
Bagchi, S., Yuan, R. & Engleman, E. G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev. Pathol. 16, 223–249 (2021).
Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci. Transl. Med 8, 328rv324–328rv324 (2016).
Yi, M., Niu, M., Xu, L., Luo, S. & Wu, K. Regulation of PD-L1 expression in the tumor microenvironment. J. Hematol. Oncol. 14, 1–13 (2021).
Dong, P., Xiong, Y., Yue, J., Hanley, S. J. & Watari, H. Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion. Front Oncol. 8, 386 (2018).
Nguyen, L. T. & Ohashi, P. S. Clinical blockade of PD1 and LAG3—potential mechanisms of action. Nat. Rev. Immunol. 15, 45–56 (2015).
Topalian, S. L., Taube, J. M., Anders, R. A. & Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275–287 (2016).
Tremblay-LeMay, R., Rastgoo, N. & Chang, H. Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway. J. Hematol. Oncol. 11, 1–16 (2018).
Li, X.-S., Li, J.-W., Li, H. & Jiang, T. Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis. Biosci. Rep. 40, BSR20200459 (2020).
Surmiak, E. et al. PD-L1 inhibitors: different classes, activities, and mechanisms of action. Int J. Mol. Sci. 22, 11797 (2021).
Li, C. et al. Peptide blocking of PD-1/PD-L1 interaction for cancer immunotherapy effect of PD-L1–targeting peptide on cancer immunotherapy. Cancer Immunol. Res. 6, 178–188 (2018).
Magiera‐Mularz, K. et al. Bioactive macrocyclic inhibitors of the PD‐1/PD‐L1 immune checkpoint. Angew. Chem. Int Ed. Engl. 56, 13732–13735 (2017).
Caldwell, C. et al. Identification and validation of a PD-L1 binding peptide for determination of PDL1 expression in tumors. Sci. Rep. 7, 1–11 (2017).
Liu, H. et al. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy. J. Immunother. Cancer 7, 1–14 (2019).
Chen, Y. et al. Engineering a high-affinity PD-1 peptide for optimized Immune cell–mediated tumor therapy. Cancer Res. Treat. 54, 362 (2022).
Abbas, A. B. et al. Design and synthesis of A PD-1 binding peptide and evaluation of its anti-tumor activity. Int J. Mol. Sci. 20, 572 (2019).
Gurung, S. et al. Phage display-identified PD-L1-binding peptides reinvigorate T-cell activity and inhibit tumor progression. Biomaterials 247, 119984 (2020).
Moon, Y. et al. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death. Theranostics 12, 1999 (2022).
Jeon, I. S. et al. Anticancer nanocage platforms for combined immunotherapy designed to harness immune checkpoints and deliver anticancer drugs. Biomaterials 270, 120685 (2021).
Zhong, T. et al. The biologically functional identification of a novel TIM3-binding peptide P26 in vitro and in vivo. Cancer Chemother. Pharm. 86, 783–792 (2020).
Zhai, W. et al. A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses. Acta Pharm. Sin. B 10, 1047–1060 (2020).
Zhou, X. et al. A novel d‐peptide identified by mirror‐image phage display blocks TIGIT/PVR for cancer immunotherapy. Angew. Chem. Int Ed999 59, 15114–15118 (2020).
Ma, P. C., Maulik, G., Christensen, J. & Salgia, R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 22, 309–325 (2003).
Xia, C. et al. Novel Peptide CM 7 Targeted c-met with antitumor activity. Molecules 25, 451 (2020).
Tam, E. M. et al. Noncompetitive inhibition of hepatocyte growth factor-dependent Met signaling by a phage-derived peptide. J. Mol. Biol. 385, 79–90 (2009).
Shen, Y. et al. Discovery of HB-EGF binding peptides and their functional characterization in ovarian cancer cell lines. Cell Death Disco. 5, 1–11 (2019).
Yan, Y., Zuo, X. & Wei, D. Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target. Stem Cells Transl. Med 4, 1033–1043 (2015).
Matzke, A., Herrlich, P., Ponta, H. & Orian-Rousseau, V. A five-amino-acid peptide blocks Met-and Ron-dependent cell migration. Cancer Res. 65, 6105–6110 (2005).
Matzke-Ogi, A. et al. Inhibition of tumor growth and metastasis in pancreatic cancer models by interference with CD44v6 signaling. Gastroenterol 150, 513–525. e510 (2016).
Chalmin, F. et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest 120, 457–471 (2010).
Gobbo, J. et al. Restoring anticancer immune response by targeting tumor-derived exosomes with a HSP70 peptide aptamer. J. Natl Cancer Inst. 108, djv330 (2016).
Stamatiades, G. A. & Kaiser, U. B. Gonadotropin regulation by pulsatile GnRH: signaling and gene expression. Mol. Cell Endocrinol. 463, 131–141 (2018).
Srkalovic, G., Wittliff, J. L. & Schally, A. V. Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res. 50, 1841–1846 (1990).
Tieva, Å., Stattin, P., Wikström, P., Bergh, A. & Damber, J. E. Gonadotropin‐releasing hormone receptor expression in the human prostate. Prostate 47, 276–284 (2001).
Huerta-Reyes, M. et al. Treatment of breast cancer with gonadotropin-releasing hormone analogs. Front Oncol. 9, 943 (2019).
Lu, Y.-S., Wong, A. & Kim, H.-J. Ovarian function suppression with luteinizing hormone-releasing hormone agonists for the treatment of hormone receptor-positive early breast cancer in premenopausal women. Front Oncol. 11, 700722 (2021).
Di Lauro, L. et al. Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. J. Hematol. Oncol. 8, 1–5 (2015).
Hofland, L. J. & Lamberts, S. W. Somatostatin receptors and disease: role of receptor subtypes. Baillieres Clin. Endocrinol. Metab. 10, 163–176 (1996).
Druker, B. J. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Eng. J. Med 344, 1038–1042 (2001).
Gurung, A., Bhattacharjee, A., Ali, M. A., Al-Hemaid, F. & Lee, J. Binding of small molecules at interface of protein–protein complex–A newer approach to rational drug design. Saudi J. Biol. Sci. 24, 379–388 (2017).
Ran, X. & Gestwicki, J. E. Inhibitors of protein–protein interactions (PPIs): an analysis of scaffold choices and buried surface area. Curr. Opin. Chem. Biol. 44, 75–86 (2018).
Mason, J. M., M. Müller, K. & Arndt, K. M. (2008). iPEP: peptides designed and selected for interfering with protein interaction and function. Biochem. Soc. Trans. 36, 1442–1447 (2008).
Bruno, B. J., Miller, G. D. & Lim, C. S. Basics and recent advances in peptide and protein drug delivery. Ther. Deliv. 4, 1443–1467 (2013).
Chen, X., Zaro, J. L. & Shen, W.-C. Fusion protein linkers: property, design and functionality. Adv. Drug Deliv. Rev. 65, 1357–1369 (2013).
Sikora, K. et al. c‐myc oncogene expression in colorectal cancer. Cancer 59, 1289–1295 (1987).
Little, C. D., Nau, M. M., Carney, D. N., Gazdar, A. F. & Minna, J. D. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306, 194–196 (1983).
Blackwood, E. M. & Eisenman, R. N. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251, 1211–1217 (1991).
Li, L., Sun, W., Zhang, Z. & Huang, Y. Time-staggered delivery of docetaxel and H1-S6A, F8A peptide for sequential dual-strike chemotherapy through tumor priming and nuclear targeting. J. Control Release 232, 62–74 (2016).
Bidwell, G. L. III et al. Thermally targeted delivery of a c-Myc inhibitory polypeptide inhibits tumor progression and extends survival in a rat glioma model. PloS one 8, e55104 (2013).
Soucek, L. et al. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene 17, 2463–2472 (1998).
Soucek, L., Nasi, S. & Evan, G. Omomyc expression in skin prevents Myc-induced papillomatosis. Cell Death Differ. 11, 1038–1045 (2004).
Soucek, L. et al. Modelling Myc inhibition as a cancer therapy. Nature 455, 679–683 (2008).
Krumlauf, R. Hox genes in vertebrate development. Cell 78, 191–201 (1994).
Bhatlekar, S., Viswanathan, V., Fields, J. Z. & Boman, B. M. Overexpression of HOXA4 and HOXA9 genes promotes self‐renewal and contributes to colon cancer stem cell overpopulation. J. Cell Physiol. 233, 727–735 (2018).
Morgan, R. et al. Antagonism of HOX/PBX dimer formation blocks the in vivo proliferation of melanoma. Cancer Res. 67, 5806–5813 (2007).
Shen, W.-F. et al. Hox homeodomain proteins exhibit selective complex stabilities with Pbx and DNA. Nucleic Acids Res. 24, 898–906 (1996).
Neuteboom, S. & Murre, C. Pbx raises the DNA binding specificity but not the selectivity of antennapedia Hox proteins. Mol. Cell Biol. 17, 4696–4706 (1997).
Plowright, L., Harrington, K., Pandha, H. & Morgan, R. HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer). Br. J. Cancer 100, 470–475 (2009).
Moore, A. R., Rosenberg, S. C., McCormick, F. & Malek, S. RAS-targeted therapies: is the undruggable drugged? Nat. Rev. Drug Disco. 19, 533–552 (2020).
Huang, L., Guo, Z., Wang, F. & Fu, L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct. Target Ther. 6, 1–20 (2021).
Garrigou, M. et al. Accelerated identification of cell active KRAS inhibitory macrocyclic peptides using mixture libraries and automated ligand identification system (ALIS) technology. J. Med. Chem. 65, 8961–8974 (2022).
Lim, S. et al. Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signaling. Chem. Sci. J. 12, 15975–15987 (2021).
Lee, Y. et al. Targeted Degradation of Transcription Coactivator SRC‐1 through the N‐Degron Pathway. Angew. Chem. Int Ed. Engl. 59, 17548–17555 (2020).
Choi, S. R., Wang, H. M., Shin, M. H. & Lim, H.-S. Hydrophobic tagging-mediated degradation of transcription coactivator SRC-1. Int J. Mol. Sci. 22, 6407 (2021).